Karras Company’s AstraZeneca AZN Stock Holding History

Karras Company’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.2M	Buy	+11,623	New	+$2.19M	2%	13
2026 Q1	–	Sell	-11,323	Closed	-$2.08M	–	62
2025 Q4	$2.08M	Buy	+11,323	New	+$1.99M	2.03%	15

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Karras Company's AZN Position: Q2 2026 in Review

Karras Company opened a new position in AstraZeneca (AZN) in Q2 2026: 11,623 shares worth $2.2M. The stake represents 2% of the portfolio and ranks #13 among its holdings. This is a return to the name: Karras Company previously reported a position in AZN as recently as Q4 2025.

Karras Company first reported a position in AZN in Q4 2025 and has held it in 2 quarters since. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Karras Company held 11,623 shares of AstraZeneca worth $2.2M as of Q2 2026.
AstraZeneca was a new Karras Company position in Q2 2026.
AstraZeneca made up 2% of Karras Company's portfolio in Q2 2026, its #13 holding.
Karras Company first reported a position in AstraZeneca in Q4 2025 and has held it in 2 quarters since.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Karras Company's 13F filing for Q2 2026, filed 23 Jul 2026.